Table 2.
A. | cMap ID | Molecule | GO counts | B. | cMap ID | Molecule |
---|---|---|---|---|---|---|
595 | resveratrol | 25+ | 573 | deferoxamine [INN] | ||
1015 | genistein | 22+ | 1068 | thioridazine [INN] | ||
970 | 5230742 | 21+ | 418 | haloperidol [INN] | ||
1068 | thioridazine [INN] | 20+ | 921 | sirolimus [INN] | ||
573 | deferoxamine [INN] | 20+ | 1080 | sirolimus [INN] | ||
1004 | trifluoperazine [INN] | 19+ | 906 | calmidazolium | ||
991 | tretinoin [INN] | 18- | 904 | 5109870 | ||
871 | ionomycin | 18+ | 1075 | fluphenazine [INN] | ||
921 | sirolimus [INN] | 17+ | 977 | wortmannin | ||
444 | clofibrate [INN] | 17- | 417 | thioridazine [INN] |
The top 10 instances sharing the largest number of significantly affected GOMs with bone marrow cells form hypoxia model are listed in A and the top 10 instances resulted from distance comparison method are listed in B.
Detailed parameter settings: GO mode: BP; P-value: < 0.05.